Receptors, Vasopressin
-
Subject Areas on Research
- A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure.
- Age and sex differences in oxytocin and vasopressin V1a receptor binding densities in the rat brain: focus on the social decision-making network.
- Allosteric activation of proto-oncogene kinase Src by GPCR-beta-arrestin complexes.
- Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors.
- Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization.
- Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.
- Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
- BiPS, a photocleavable, isotopically coded, fluorescent cross-linker for structural proteomics.
- Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.
- Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.
- Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.
- Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor.
- G Protein and β-arrestin signaling bias at the ghrelin receptor.
- G protein G(alpha)o is essential for vomeronasal function and aggressive behavior in mice.
- Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
- Neural correlates of mating system diversity: oxytocin and vasopressin receptor distributions in monogamous and non-monogamous Eulemur.
- Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction.
- Phosphorylation analysis of G protein-coupled receptor by mass spectrometry: identification of a phosphorylation site in V2 vasopressin receptor.
- Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
- Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination.
- Respiration during acute hypoxia: angiotensin- and vasopressin-receptor blocks.
- Structural studies of phosphorylation-dependent interactions between the V2R receptor and arrestin-2.
- Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide.
- Structure of an endosomal signaling GPCR-G protein-β-arrestin megacomplex.
- The potential repertoire of the innate immune system in the bladder: expression of pattern recognition receptors in the rat bladder and a rat urothelial cell line (MYP3 cells).
- Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
- Universal nomenclature for oxytocin-vasotocin ligand and receptor families.
- Vasopressin receptor antagonists.
- Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.
- Vasopressin: a new target for the treatment of heart failure.
- Ventilatory and metabolic effects of hypercapnia in conscious rats: AVP V1 receptor block.
-
Keywords of People
- O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology